For over thirty years the benzodiazepines monopolised not only the anxiolytic market but also clinical and animal research in anxiety. Indeed many animal tests developed since the 1960s have been optimised for the benzodiazepines and some programmes have even screened candidates as potential anxiolytics on their benzodiazepine-like side-effects rather than their anxiolytic activity. With the realisation of the drawbacks of the benzodiazepines, namely their potential for tolerance and dependency, there has been a renewed interest in alternative anxiolytics both from existing drugs such as the tricyclic and monoamine oxidase antidepressants and from newer agents such as buspirone. In addition anxiety is no longer considered to be a unique entity but rather an umbrella term for a series of specific anxiety disorders such as panic disorder without or with agoraphobia, generalised anxiety disorder (GAD), specific phobias, social phobias and post-traumatic stress disorder (PTSD). These new clinical categories have opened another dimension in the therapy of anxiety requiring the optimisation of treatments for different syndromes. This book is a critical review of today's anxiolytics and those that may become the anxiolytics of tomorrow. What is clear is that currently there are few clinically satisfactory alternatives to the benzodiazepines for the treatment of acute anxiety. For chronic anxiety, it is generally agreed that benzodi azepines are not the treatment of first choice. The tricyclic and monoamine oxidase antidepressants, the serotonin reuptake inhibitors and buspirone offer better solutions for chronic anxiety but they are still far from being ideal.
Die Inhaltsangabe kann sich auf eine andere Ausgabe dieses Titels beziehen.
For over thirty years the benzodiazepines monopolised not only the anxiolytic market but also clinical and animal research in anxiety. Indeed many animal tests developed since the 1960s have been optimised for the benzodiazepines and some programmes have even screened candidates as potential anxiolytics on their benzodiazepine-like side-effects rather than their anxiolytic activity. With the realisation of the drawbacks of the benzodiazepines, namely their potential for tolerance and dependency, there has been a renewed interest in alternative anxiolytics both from existing drugs such as the tricyclic and monoamine oxidase antidepressants and from newer agents such as buspirone. In addition anxiety is no longer considered to be a unique entity but rather an umbrella term for a series of specific anxiety disorders such as panic disorder without or with agoraphobia, generalised anxiety disorder (GAD), specific phobias, social phobias and post-traumatic stress disorder (PTSD). These new clinical categories have opened another dimension in the therapy of anxiety requiring the optimisation of treatments for different syndromes. This book is a critical review of today's anxiolytics and those that may become the anxiolytics of tomorrow. What is clear is that currently there are few clinically satisfactory alternatives to the benzodiazepines for the treatment of acute anxiety. For chronic anxiety, it is generally agreed that benzodi azepines are not the treatment of first choice. The tricyclic and monoamine oxidase antidepressants, the serotonin reuptake inhibitors and buspirone offer better solutions for chronic anxiety but they are still far from being ideal.
This volume highlights today's and tomorrow's anxiolytics, examining in details the strengths and weaknesses of different classes of proposed anxiolytics. Each chapter is written by an acknowledged international expert actively working in the field. Essentially intended for researchers in academia and the pharmaceutical industry, the book is also of interest to psychiatrists and medical students interested in this specialty. In addition those in the pharmaceutical industry (strategic marketing, licencing, portfolio management...) who need to be able to foresee future developments in the anxiolytic drug scene will find the insights obtained from this volume to be invaluable. By putting side by side today's and tomorrow's anxiolytics the text underlines the progress made (and sometimes the lack of it) in different areas. After reading this book, the reader should have a good "feeling" of where the anxiolytic field is going in the next few years.
„Über diesen Titel“ kann sich auf eine andere Ausgabe dieses Titels beziehen.
EUR 36,00 für den Versand von Schweiz nach USA
Versandziele, Kosten & DauerEUR 3,43 für den Versand innerhalb von/der USA
Versandziele, Kosten & DauerAnbieter: Lucky's Textbooks, Dallas, TX, USA
Zustand: New. Bestandsnummer des Verkäufers ABLIING23Apr0316110058890
Anzahl: Mehr als 20 verfügbar
Anbieter: Ria Christie Collections, Uxbridge, Vereinigtes Königreich
Zustand: New. In. Bestandsnummer des Verkäufers ria9783764360320_new
Anzahl: Mehr als 20 verfügbar
Anbieter: California Books, Miami, FL, USA
Zustand: New. Bestandsnummer des Verkäufers I-9783764360320
Anzahl: Mehr als 20 verfügbar
Anbieter: online-buch-de, Dozwil, Schweiz
Hardcover Sep 01, 2000. Zustand: gebraucht; sehr gut. (!) anderes Coverbild, Auflage 2000, textsauber und gepflegt. Bestandsnummer des Verkäufers 561-4-18
Anzahl: 1 verfügbar
Anbieter: Basi6 International, Irving, TX, USA
Zustand: Brand New. New. US edition. Expediting shipping for all USA and Europe orders excluding PO Box. Excellent Customer Service. Bestandsnummer des Verkäufers ABEOCT25-246966
Anzahl: 1 verfügbar
Anbieter: Romtrade Corp., STERLING HEIGHTS, MI, USA
Zustand: New. This is a Brand-new US Edition. This Item may be shipped from US or any other country as we have multiple locations worldwide. Bestandsnummer des Verkäufers ABNR-82615
Anzahl: 1 verfügbar
Anbieter: ALLBOOKS1, Direk, SA, Australien
Bestandsnummer des Verkäufers SHAK246966
Anzahl: 1 verfügbar
Anbieter: Kennys Bookshop and Art Galleries Ltd., Galway, GY, Irland
Zustand: New. Highlights anxiolytics, examining in details the strengths and weaknesses of different classes of proposed anxiolytics. This work is suitable for researchers in academia and the pharmaceutical industry, and also for psychiatrists and medical students interested in this specialty. Editor(s): Briley, Mike; Nutt, David J. Series: Milestones in Drug Therapy. Num Pages: 190 pages, biography. BIC Classification: MBGR; MMGW; MMH. Category: (P) Professional & Vocational; (UP) Postgraduate, Research & Scholarly. Dimension: 234 x 156 x 12. Weight in Grams: 454. . 2000. Hardback. . . . . Bestandsnummer des Verkäufers V9783764360320
Anzahl: 15 verfügbar
Anbieter: moluna, Greven, Deutschland
Zustand: New. For over thirty years the benzodiazepines monopolised not only the anxiolytic market but also clinical and animal research in anxiety. Indeed many animal tests developed since the 1960s have been optimised for the benzodiazepines and some programmes have ev. Bestandsnummer des Verkäufers 5279259
Anzahl: Mehr als 20 verfügbar
Anbieter: Kennys Bookstore, Olney, MD, USA
Zustand: New. Highlights anxiolytics, examining in details the strengths and weaknesses of different classes of proposed anxiolytics. This work is suitable for researchers in academia and the pharmaceutical industry, and also for psychiatrists and medical students interested in this specialty. Editor(s): Briley, Mike; Nutt, David J. Series: Milestones in Drug Therapy. Num Pages: 190 pages, biography. BIC Classification: MBGR; MMGW; MMH. Category: (P) Professional & Vocational; (UP) Postgraduate, Research & Scholarly. Dimension: 234 x 156 x 12. Weight in Grams: 454. . 2000. Hardback. . . . . Books ship from the US and Ireland. Bestandsnummer des Verkäufers V9783764360320
Anzahl: 15 verfügbar